By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Biogen Idec, Inc. (Massachusetts) 

14 Cambridge Center

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-679-2000 Fax: 617-679-2617

Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.

Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.

With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.

For product labeling, press releases and additional information about the company, please visit

Key Statistics

Ownership: Public

Web Site: Biogen
Employees: 1700
Symbol: BIIB



NeoGenesis Pharmaceuticals, Inc.  Small molecule High Throughput Screening for multiple programs (6/01)

GPC Biotech, Inc.  HIV TAT-derived transport polytptides and methods of their use (5/01) - this was an outlicense from a research

ICOS Corporation  LFA-1 small molecule for psoriasis (7/01)

Elan  (crohn's & MS)

Dyax  Antibody phage display

Dow AgroSciences LLC 


Sangamo BioSciences 


Company News
Swedish Orphan Biovitrum And Biogen (BIIB)’s ELOCTA (rFVIIIFc) Approved In Europe For The Treatment Of Haemophilia A 11/24/2015 10:50:56 AM
Samsung Bioepis, Biogen (BIIB) Biosimilar is About to Take a Huge Chunk of Pfizer (PFE)'s Profits 11/20/2015 6:34:01 AM
Former Biogen (BIIB) Exec Doug Williams to Head Startup Codiak BioSciences 11/17/2015 4:11:51 AM
Who Can Gobble Up Biogen (BIIB), or Who Can Biogen Buy 11/16/2015 6:51:52 AM
After Dropping the "Biogen (BIIB) Bombshell," CEO Turns R&D Focus to Neurological Diseases Like Alzheimer's 11/12/2015 6:43:03 AM
As Biogen (BIIB) Cuts 11% of Staff, Company Doubles Down on Clinical Trials 11/5/2015 6:06:11 AM
Regulus (RGLS) Achieves All Research Milestones In Collaboration With Biogen (BIIB) To Identify microRNA Biomarkers For Multiple Sclerosis 10/28/2015 7:42:17 AM
Biogen (BIIB)'s Natalizumab Did Not Meet Primary and Secondary Endpoints in Late-Stage Study 10/21/2015 6:14:42 AM
In Face of Dropping Stocks and Failed Phase III, Biogen (BIIB) Restructures, Slashes Programs and Lays off 880 People 10/21/2015 6:06:57 AM
Analysts Try to Pry Open Biogen (BIIB) as Stock Continues Slump and Investors Jump Ship 10/15/2015 6:14:07 AM